Clinical trialNCT04862221Active, not recruitingPhase 2Interventional

TReatment for ImmUne Mediated PathopHysiology

SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Enrollment44Acute Liver FailureAcute Liver InjuryFulminant Hepatic FailureHepatic EncephalopathyImmune Dysregulation

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Averell Sherker, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Study Director
clinicaltrials.gov ↗
Ed Doo, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Study Director
clinicaltrials.gov ↗
Estella M Alonso, MD
Ann & Robert H Lurie Children's Hospital of Chicago
Principal Investigator
clinicaltrials.gov ↗
Valerie L Durkalski-Mauldin, PhD
Medical University of South Carolina
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Children'S Hospital Los Angeles
Los Angeles, California, United States
Lucile Packard Children'S Hospital
Palo Alto, California, United States
Rady Children'S Hospital
San Diego, California, United States
Children'S Hospital Colorado
Aurora, Colorado, United States
Ann & Robert H. Lurie Children'S Hospital of Chicago
Chicago, Illinois, United States
Riley Hospital for Children
Indianapolis, Indiana, United States
Children'S Hospital Boston
Boston, Massachusetts, United States
the Children'S Mercy Hospital
Kansas City, Missouri, United States
St. Louis Children'S Hospital
St Louis, Missouri, United States
Nyp Morgan Stanley Children'S Hospital
New York, New York, United States
Cincinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States
the Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Children'S Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States
Children'S Hospital Vanderbilt
Nashville, Tennessee, United States
Ut Southwestern Medical Center Children'S Health
Dallas, Texas, United States
Texas Children'S Hospital
Houston, Texas, United States
Seattle Children'S Hospital
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Diphenhydramine →Lymphocyte immune globulin, anti-thymocyte globulin →High-dose methylprednisoloneMethylprednisolone →Placebo for infusionsPlacebo for prednisolonePrednisolone →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 9 Feb 2022
Primary completion: 3 Aug 2026
Completion: 28 Feb 2027
Last update posted: 12 Aug 2026
Registered enrollment: 44
Registry id: NCT04862221

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.